At Worldwide, we bring endpoints precision, biomarker-driven patient identification and a proven global site network to asthma and chronic cough programs across Phase I-IV
We’ll connect you with the right Asthma & Cough Specialist
Why Asthma & Chronic Cough Programs Demand Specialized Support
We bring together site selection built on documented enrollment history, biomarker screening infrastructure that holds eligibility consistent, and spirometry quality managed above industry benchmark, to help our partners de-risk enrollment and protect the submission.
Exacerbation history, blood eosinophil thresholds, FEV1 criteria, and concomitant medication restrictions narrow eligibility at any given point, and asthma trials running in parallel compete for the same treatment-experienced patients.
Eosinophilic and severe asthma subtypes require blood eosinophil counts, FeNO testing, and other biomarker criteria that add complexity at screening and raise eligibility risk across global sites.
Spirometry variability across sites separates a clean regulatory submission from one that requires adjudication, particularly in global programs where ATS/ERS guideline adherence is inconsistent.

Partnership & Approach
Sponsors have direct access to the respiratory leaders who have delivered asthma programs across dozens of countries, from protocol design through database lock. On multi-protocol programs, resourcing is assigned at program level rather than study by study, which removes duplication and holds activation timelines.
14 respiratory studies over the past five years across 2,029 sites, 4,951 patients, and 42 countries, including one of the largest asthma programs run in that period.
Participants
Sites
Countries
A four-study global asthma program run as one program rather than four separate studies, with 170 sites activated in under 90 days and 67% retention into the extension study.

Acceptable PFT Quality
Spirometry quality above the 91% industry benchmark, with training and oversight aligned to ATS/ERS 2019 standards across global sites.

Respiratory Studies
Countries
Five years of delivery across 2,029 sites and 4,951 patients, spanning eosinophilic asthma, IPF, interstitial lung disease, cystic fibrosis, and allergic bronchopulmonary aspergillosis.

Why Worldwide for Asthma & Cough Trials
Established pediatric research infrastructure for asthma indications, spanning regulatory, pharmacometric, and global trial delivery capability.
Equipment quality, data review, and ongoing site coaching integrated into every respiratory program through a strategic partnership with Clario, alongside specialized respiratory guideline training for CRAs and site staff.
Established site relationships across North America, Latin America, Europe, and Asia-Pacific, selected on asthma enrollment history, real-world treatment access and data quality rather than legacy lists.
Frequently Asked Questions
We have answered the questions sponsors ask most often about asthma and chronic cough programs. If yours isn’t here, our respiratory team is happy to help.
Sites are selected on documented enrollment history, real-world treatment access, and established investigator relationships rather than legacy site lists, prioritizing geographies where eligible patients are active and reachable.
Our spirometry quality runs at 94% acceptable against a 91% industry benchmark, with CRA and medical expert training aligned to ATS/ERS 2019 standards and continuous data monitoring across all sites.
Yes. Worldwide has managed asthma programs requiring blood eosinophil counts, FeNO testing and other biomarker screening criteria across Phase I-IV, with site infrastructure and training built around biomarker-dependent eligibility.
Yes. Worldwide supports both through an established center of excellence in pediatric clinical research, with integrated regulatory, pharmacometric and global trial delivery capability.
On a four-study global asthma program across Asia Pacific, Europe, Latin America, and North America, resourcing was assigned at program level rather than protocol by protocol, removing duplication of effort and accelerating internal reviews. Subject matter experts developed specialized respiratory guideline training for CRAs and site staff, which reduced protocol deviations and sped activation. The program enrolled 2,000+ participants across 995 sites in 31 countries, with 170 sites activated in under 90 days and 67% retention into the extension study.